title: The suppression of TRIM21 and the accumulation of IFN-α play crucial roles in the pathogenesis of osteonecrosis of the femoral head.
abstract: Osteonecrosis of the femoral head (ONFH), the pathogenesis of which remains unclear, has been observed in autoimmune disease patients treated with corticosteroids. Recently, it has been shown that anti-tripartite motif-containing 21 (TRIM21) autoantibodies, which are often present in patients with systemic lupus erythematosis and Sjögren's syndrome, inhibit the E3 ligase activity of TRIM21. TRIM21 negatively regulates nuclear factor-κB (NF-κB) and interferon regulatory factors (IRFs) 3 and 7, three downstream transcription factors, via toll-like receptor 4 signaling. The aim of this study was to clarify the role of TRIM21 in the pathogenesis of ONFH using an animal model. Male Wistar rats were injected with lipopolysaccharide (LPS) twice and with methylprednisolone (MPSL) or saline three times. N-acetyl cysteine (NAC) was administered either concurrently with MPSL or once daily for the 3 days following the last MPSL injection. The incidence of ONFH in the MPSL group was 23.5%. Co-treatment of NAC and MPSL increased the incidence of ONFH to 55.6%. MPSL treatment decreased the activity of NF-κB in the liver and significantly increased the activity of both IRF3 and IRF7. No significant differences were observed in the activity of any of these three transcription factors between the MPSL and the co-treatment groups. In the femoral head, co-treatment with NAC and MPSL significantly decreased the expression of TRIM21 at 3 h and significantly increased the expression of interferon (IFN)-α at 24 h when compared with the MPSL group. IFN-α is known to induce cell death. These findings suggest that the suppression of TRIM21 in the femoral head causes an accumulation of IFN-α, which in turn leads to the development of ONFH. In conclusion, the suppression of TRIM21 resulting from altered NF-κB and IRF homeostasis accelerates the ONFH in rats treated with corticosteroids following LPS administration.
authors: Department of Legal Medicine and Molecular Alcohology, Sapporo Medical University School of Medicine, Sapporo, Japan.
authors: Kenji
authors: K
authors: Tateda
authors: Shunichiro
authors: S
authors: Okazaki
authors: Satoshi
authors: S
authors: Nagoya
authors: Ryuichi
authors: R
authors: Katada
authors: Keisuke
authors: K
authors: Mizuo
authors: Satoshi
authors: S
authors: Watanabe
authors: Toshihiko
authors: T
authors: Yamashita
authors: Hiroshi
authors: H
authors: Matsumoto
mesh_terms: D000818:Animals; D024202:Electrophoretic Mobility Shift Assay; D005271:Femur Head Necrosis / Q000378:metabolism / Q000503:physiopathology*; D007150:Immunohistochemistry; D016898:Interferon-alpha / Q000378:metabolism*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D060888:Real-Time Polymerase Chain Reaction; D000070584:Tripartite Motif Proteins; D044767:Ubiquitin-Protein Ligases / Q000502:physiology*; D000099208:TRIM21 Protein
chemical_list: D016898:Interferon-alpha; D000070584:Tripartite Motif Proteins; D044767:Ubiquitin-Protein Ligases; C576159:Trim21 protein, rat; D000099208:TRIM21 Protein